Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Stage II Colon Cancer Risk Assessment

NCCN and ASCO guidelines recommend assessing high-risk features in patients with Stage II Colon Cancer (T3N0/T4N0) to decide on adjuvant chemotherapy.

Evidence-based context for fast calculator use

Purpose:
Stage II Colon Cancer Risk Assessment identifies high-risk pathologic features to guide adjuvant chemotherapy decisions per NCCN and ASCO guidelines.
Population:
patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model
Factors:
T4 Tumor?, Fewer than 12 Lymph Nodes examined?, Poorly Differentiated Histology?, Lymphovascularor Perineural Invasion?, Presentation with Obstruction or Perforation?, MMR Status
Reference:
Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419. (Updated in subsequent NCCN guidelines).
HomeStage II Colon Cancer Risk Assessment
Pin your most used calculators here by clicking the star in the dropdown.

Stage II Colon Cancer Risk Assessment

Clinical Context & Background

NCCN and ASCO guidelines recommend assessing high-risk features in patients with Stage II Colon Cancer (T3N0/T4N0) to decide on adjuvant chemotherapy. Patients with high-risk features may benefit from chemotherapy (e.g., CAPOX/FOLFOX or 5-FU), while low-risk patients may be observed.
Primary Source EvidenceBenson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408-3419. (Updated in subsequent NCCN guidelines).
Formula Logic
Presence of any high-risk factor increases recurrence risk.

Reference Data

Risk GroupRecommendation
Low Risk (No factors)Observation or Fluoropyrimidine mono-therapy
High Risk (Any factor)Consider Adjuvant Chemotherapy (Doublet or Mono)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Stage II Colon Cancer Risk Assessment when stage II Colon Cancer Risk Assessment identifies high-risk pathologic features to guide adjuvant chemotherapy decisions per NCCN and ASCO guidelines.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk (No factors) through High Risk (Any factor).
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm primary site, histology, stage, surgery status, systemic-treatment timing, and disease-specific guideline before applying the result.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Do not transfer thresholds across colorectal, GIST, gastric, appendiceal, and other peritoneal malignancies.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model

How to apply this result

For a representative case, verify T4 Tumor?, Fewer than 12 Lymph Nodes examined?, Poorly Differentiated Histology?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

GI, GIST & Peritoneal hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

Modified Glasgow Prognostic Score (mGPS)Fong Clinical Risk Score (CRS)Peritoneal Carcinomatosis Index (PCI)

Frequently Asked Questions

When should Stage II Colon Cancer Risk Assessment be used?

Use it for patients with the specific gastrointestinal, stromal, colorectal, or peritoneal disease context described by the model when all required inputs and the intended clinical setting are confirmed.

Can Stage II Colon Cancer Risk Assessment determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.